324 related articles for article (PubMed ID: 31088326)
1. Clinical value of fecal calprotectin.
Ricciuto A; Griffiths AM
Crit Rev Clin Lab Sci; 2019 Aug; 56(5):307-320. PubMed ID: 31088326
[TBL] [Abstract][Full Text] [Related]
2. Both fecal calprotectin and fecal immunochemical tests are useful in children with inflammatory bowel disease.
Shimizu H; Ebana R; Kudo T; Sato T; Hara T; Hosoi K; Usami M; Yoshida M; Takeuchi I; Nakase H; Iwama I; Arai K; Shimizu T
J Gastroenterol; 2022 May; 57(5):344-356. PubMed ID: 35165800
[TBL] [Abstract][Full Text] [Related]
3. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
Sidler MA; Leach ST; Day AS
Inflamm Bowel Dis; 2008 Mar; 14(3):359-66. PubMed ID: 18050298
[TBL] [Abstract][Full Text] [Related]
4. [Fecal calprotectin as a biomarker effectiveness of various interventions in patients with inflammatory bowel disease].
Lazebnik LB; Guseĭn-Zade MG; Efremov LI; Sagynbaeva VÉ; Kniazev OV
Eksp Klin Gastroenterol; 2013; (8):11-6. PubMed ID: 24933942
[TBL] [Abstract][Full Text] [Related]
5. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
6. Pomegranate juice to reduce fecal calprotectin levels in inflammatory bowel disease patients with a high risk of clinical relapse: Study protocol for a randomized controlled trial.
Scaioli E; Belluzzi A; Ricciardiello L; Del Rio D; Rotondo E; Mena P; Derlindati E; Danesi F
Trials; 2019 Jun; 20(1):327. PubMed ID: 31171016
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease.
Sipponen T; Kolho KL
Scand J Gastroenterol; 2015 Jan; 50(1):74-80. PubMed ID: 25523558
[TBL] [Abstract][Full Text] [Related]
9. Fecal Calprotectin in Gastrointestinal Disease.
Murray J; Kok KB; Ayling RM
Clin Chem; 2023 Jul; 69(7):699-710. PubMed ID: 37228058
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
[TBL] [Abstract][Full Text] [Related]
11. Calprotectin or Lactoferrin: Do They Help.
Wright EK
Dig Dis; 2016; 34(1-2):98-104. PubMed ID: 26982329
[TBL] [Abstract][Full Text] [Related]
12. Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactoferrin.
Sipponen T
Dig Dis; 2013; 31(3-4):336-44. PubMed ID: 24246984
[TBL] [Abstract][Full Text] [Related]
13. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?
Di Ruscio M; Vernia F; Ciccone A; Frieri G; Latella G
Inflamm Bowel Dis; 2017 Dec; 24(1):78-92. PubMed ID: 29272479
[TBL] [Abstract][Full Text] [Related]
14. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases.
Dulai PS; Peyrin-Biroulet L; Danese S; Sands BE; Dignass A; Turner D; Mantzaris G; Schölmerich J; Mary JY; Reinisch W; Sandborn WJ
Gastroenterology; 2019 Oct; 157(4):1032-1043.e1. PubMed ID: 31228441
[TBL] [Abstract][Full Text] [Related]
15. Utility of faecal calprotectin analysis in adult inflammatory bowel disease.
Smith LA; Gaya DR
World J Gastroenterol; 2012 Dec; 18(46):6782-9. PubMed ID: 23239916
[TBL] [Abstract][Full Text] [Related]
16. Fecal Calprotectin.
Ayling RM; Kok K
Adv Clin Chem; 2018; 87():161-190. PubMed ID: 30342711
[TBL] [Abstract][Full Text] [Related]
17. [Fecal Calprotectin in Inflammatory Bowel Disease].
Lee J
Korean J Gastroenterol; 2016 May; 67(5):233-7. PubMed ID: 27206433
[TBL] [Abstract][Full Text] [Related]
18. Excluding inflammatory bowel disease in the irritable bowel syndrome patient: how far to go?
Nemakayala DR; Cash BD
Curr Opin Gastroenterol; 2019 Jan; 35(1):58-62. PubMed ID: 30407259
[TBL] [Abstract][Full Text] [Related]
19. [Fecal calprotectin as a diagnostic marker of inflammatory bowel disease].
Kostrzewska P; Całkosiński A; Majewski M; Malinowski K
Pol Merkur Lekarski; 2022 Feb; 50(295):58-61. PubMed ID: 35278302
[TBL] [Abstract][Full Text] [Related]
20. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease.
Konikoff MR; Denson LA
Inflamm Bowel Dis; 2006 Jun; 12(6):524-34. PubMed ID: 16775498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
